← Leaderboards
Nishant Agrawal
Johns Hopkins University
$4,719,309
Attributed
$8,747,413
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,747,413 · 6
By mechanism
RC2$2,483,116 · 1
U01$2,111,526 · 1
R01$1,930,019 · 1
P50$1,785,352 · 2
R21$437,400 · 1
Top collaborators
- Mark W. Lingen5 shared
- Chetan Bettegowda3 shared
- Nickolas Papadopoulos3 shared
- David Sidransky2 shared
- Victor E Velculescu2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Joseph A Califano$16,242,638
- Patrick Kyongmin Ha$2,960,780
- David Sidransky$59,922,938
- Daria A Gaykalova$2,179,372
- Evgeny (eugene) G Izumchenko$1,669,074
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMutationMolecularMorbidity - Disease RateUnited StatesSalivaBaseHead And Neck CancerTumorBiological MarkersMortalityDetectionScreeningPrognosticHead And Neck Squamous Cell CarcinomaPathogenesisGenesSalivarySomatic MutationDiagnosisModalityMalignant - DescriptorCancer DiagnosisProcedures
Grant awards (17)
Multi-analyte Approach for Earlier Detection of Cancers in Non Plasma Biofluids$708,799
U01 · FY2025 · CA
Multi-analyte Approach for Earlier Detection of Cancers in Non Plasma Biofluids$415,618
U01 · FY2024 · CA
Somatic Mutations in Tissue and Saliva as Prognostic and Screening Biomarkers for Oral Premalignancy$378,308
R01 · FY2024 · DE · contact PI
Multi-analyte Approach for Earlier Detection of Cancers in Non Plasma Biofluids$987,109
U01 · FY2023 · CA
Somatic Mutations in Tissue and Saliva as Prognostic and Screening Biomarkers for Oral Premalignancy$386,028
R01 · FY2023 · DE · contact PI
Somatic Mutations in Tissue and Saliva as Prognostic and Screening Biomarkers for Oral Premalignancy$396,183
R01 · FY2022 · DE · contact PI
Somatic Mutations in Tissue and Saliva as Prognostic and Screening Biomarkers for Oral Premalignancy$384,750
R01 · FY2021 · DE · contact PI
Somatic Mutations in Tissue and Saliva as Prognostic and Screening Biomarkers for Oral Premalignancy$384,750
R01 · FY2020 · DE · contact PI
HNSCC: From Cancer Genomics to Personalized Biomarkers$352,902
P50 · FY2016 · DE · contact PI
HNSCC: From Cancer Genomics to Personalized Biomarkers$353,099
P50 · FY2015 · DE · contact PI
Improving epidermal growth factor receptor-targeted of HNSCC by inhibition of tr$362,354
P50 · FY2014 · DE · contact PI
HNSCC: From Cancer Genomics to Personalized Biomarkers$353,317
P50 · FY2014 · DE · contact PI
HNSCC: From Cancer Genomics to Personalized Biomarkers$363,680
P50 · FY2013 · DE · contact PI
Genome Wide Discovery of Molecular Alterations in Salivary Gland Tumors$194,400
R21 · FY2013 · DE · contact PI
Genome Wide Discovery of Molecular Alterations in Salivary Gland Tumors$243,000
R21 · FY2012 · DE · contact PI
Genone-wide Discovery of Molecular Alterations in Head and Neck Cancer$1,252,565
RC2 · FY2010 · DE
Genone-wide Discovery of Molecular Alterations in Head and Neck Cancer$1,230,551
RC2 · FY2009 · DE